510(k) Report

510(k) · Cleared

Cleared

RelieVRx (Pico G3)

K251519510(k) TraditionalCleared Aug 13, 202589-day reviewClass II21 CFR 890.5800

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Appliedvr · QRA Virtual Reality Behavioral Therapy Device For Pain Relief

Cleared on Aug 13, 2025 as substantially equivalent to K243417 (Appliedvr, 2024) after an 89-day review. Its family tree reaches back 2 generations to 2021.

Decided
Aug 13, 2025
Review
89 days
Class
Class II
Product code
QRA
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN210014 (2021). No later device cites it as a predicate yet.

DEN210014 · EaseVRx · Appliedvr, Inc. · 2021K243417 · RelieVRx · Appliedvr · 20242020202220242026
  1. Root · 2 generations backDEN210014 EaseVRxAppliedvr, Inc. · 2021
  2. 1 generation backK243417 RelieVRxAppliedvr · 2024
  3. This deviceK251519 RelieVRx (Pico G3)Appliedvr · 2025
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN210014EaseVRxAppliedvr, Inc.2021—
−1K243417RelieVRxAppliedvr2024—
0 (this device)K251519RelieVRx (Pico G3)Appliedvr2025—
FIG. 1 — Lineage of K251519, 2021–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QRA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QRA device

  1. #1 K243417 RelieVRxscore 11.5 · 1 generation · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K243417RelieVRx
Summary page 5
…reality behavioral therapy device for pain relief. Class:​ II Product Code:​ QRA Predicate Device:​ RelieVRx (K243417) Indications for Use RelieVRx is a prescription-use immersive virtual reality system intended to provide adjunctive treatment…
Appliedvr2024—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 4 years and passes through 2 companies; a new generation was cleared every 3.0 years on median.
  • None of the 2 ancestors has a recall.

How does its category compare?

All QRA devices

QRA Virtual Reality Behavioral Therapy Device For Pain Relief: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.

FDA decisions per year · QRA

1in 2025

2021: 12023: 22024: 12025: 12026 (partial year): 1
2007high 2 (2023) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QRA

Too few QRA 510(k)s in any year since 2007 to give a median.

Recalls per year · QRA

No recall names QRA since 2007.

Adverse event reports per year · QRA

No MAUDE report names QRA since 2007.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20211—00
20220—00
20232—00
20241—00
20251—00
20261—0—

What is it indicated for?

RelieVRx is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on

cognitive behavioral therapy skills and other evidence based behavioral methods for patients (age 18 and older) with a

diagnosis of chronic lower back-pain (defined as moderate to severe pain lasting longer than three months). The device is

intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K251519: RelieVRx (Pico G3).” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K251519

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026